Fennec Pharmaceuticals (FENC) CEO Jeffrey Hackman Receives 1,159-Share Award

What Happened
Jeffrey S. Hackman, CEO of Fennec Pharmaceuticals (FENC), acquired 1,159 shares on 2026-07-31 through the release of previously restricted shares. The shares were recorded at $0.00 per share (total reported value $0), reflecting the vesting/release of an earlier award rather than a market purchase or sale.

Key Details

• Transaction date: 2026-07-31; Filing date (Form 4): 2026-08-03 (filed within the typical 2-business-day window).
• Transaction type/code: Award/other acquisition (code A).
• Shares acquired: 1,159; Price: $0.00; Reported total value: $0.
• Footnote: Shares represent release from restriction of an award granted on 2025-03-28.
• Shares owned after the transaction: Not specified in the provided excerpt—see the full Form 4 for post-transaction beneficial ownership.

Context
This was a vesting/release of previously granted restricted shares (an award becoming unrestricted). Such transactions do not involve an open-market purchase or sale and therefore are not direct signals of a buy/sell decision. For the precise post-transaction stake and any tax-withholding or share-retention details, consult the complete Form 4 filing (accession 0001926254-26-000012).